Published in J Biol Chem on May 09, 2007
Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog (2010) 2.60
Pak protein kinases and their role in cancer. Cancer Metastasis Rev (2009) 2.44
PAK1 as a therapeutic target. Expert Opin Ther Targets (2010) 1.48
PAK signaling in cancer. Cell Logist (2012) 1.27
ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther (2008) 1.19
Cullins and cancer. Genes Cancer (2010) 1.16
Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Crit Rev Biochem Mol Biol (2013) 1.08
E74-like factor 3 (ELF3) impacts on matrix metalloproteinase 13 (MMP13) transcriptional control in articular chondrocytes under proinflammatory stress. J Biol Chem (2011) 1.04
Moonlighting proteins in cancer. Cancer Lett (2015) 0.82
Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis. Hum Pathol (2009) 0.82
Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism. Mol Cancer (2011) 0.80
The uncovering of ESE-1 in human neutrophils: implication of its role in neutrophil function and survival. Genes Immun (2015) 0.77
Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton. Cell Death Dis (2014) 0.76
ESE-1 in Early Development: Approaches for the Future. Front Cell Dev Biol (2016) 0.75
E74-like factor 3 and nuclear factor-κB regulate lipocalin-2 expression in chondrocytes. J Physiol (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity (2006) 2.95
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst (2006) 2.71
Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol (2002) 2.45
Pak protein kinases and their role in cancer. Cancer Metastasis Rev (2009) 2.44
MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res (2008) 2.32
Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle (2009) 2.31
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology (2012) 2.23
Modified Trachlight for management of difficult pediatric airway. Paediatr Anaesth (2008) 2.19
SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell (2010) 2.18
Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol (2002) 2.18
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15
Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res (2005) 2.09
MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol (2010) 2.03
The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol (2002) 2.03
Suicide an emerging public health problem: evidence from rural Haryana, India. Indian J Public Health (2013) 2.03
Cystatin C-based glomerular filtration rate estimating equations in early chronic kidney disease. Indian Pediatr (2014) 2.02
Metastasis tumor antigens, an emerging family of multifaceted master coregulators. J Biol Chem (2006) 2.00
Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell (2004) 1.93
Taxonomic studies on genus Tetramorium Mayr (Hymenoptera, Formicidae) with report of two new species and three new records including a tramp species from India with a revised key. Zookeys (2012) 1.92
The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A (2004) 1.89
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J (2002) 1.75
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res (2006) 1.72
Retracted Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. J Biol Chem (2010) 1.71
p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem (2003) 1.70
Retracted Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development (2004) 1.67
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem (2008) 1.66
Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res (2009) 1.66
MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A (2006) 1.66
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem (2005) 1.65
Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res (2013) 1.63
Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging (2014) 1.63
Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci (2006) 1.63
The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol (2004) 1.61
Disseminated tuberculosis masquerading as metastatic breast carcinoma on PET-CT. Clin Nucl Med (2008) 1.61
Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol (2010) 1.60
Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res (2004) 1.59
Biliary microlithiasis in patients with idiopathic acute pancreatitis and unexplained biliary pain: response to therapy. J Gastroenterol Hepatol (2004) 1.59
P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res (2006) 1.58
RNA sequencing of cancer reveals novel splicing alterations. Sci Rep (2013) 1.57
Retracted Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. J Biol Chem (2009) 1.56
Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer (2010) 1.54
Thyroid scintigraphy in detecting dual ectopic thyroid: a review. Eur J Nucl Med Mol Imaging (2008) 1.54
Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res (2009) 1.53
HSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response. J Biol Chem (2009) 1.52
Community Perception and Client Satisfaction about the Primary Health Care Services in an Urban Resettlement Colony of New Delhi. Indian J Community Med (2008) 1.52
AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood (2008) 1.52
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem (2009) 1.52
Dyke-Davidoff-Masson syndrome. Indian Pediatr (2008) 1.51
Nuclear receptor coregulators in cancer biology. Cancer Res (2009) 1.51
Hallmarks of mechanochemistry: from nanoparticles to technology. Chem Soc Rev (2013) 1.51
UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci (2008) 1.51
Functional inactivation of a transcriptional corepressor by a signaling kinase. Nat Struct Biol (2003) 1.50
Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal (2007) 1.48
Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol (2007) 1.48
Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation. Ann Thorac Med (2011) 1.47
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A (2006) 1.46
Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett (2005) 1.44
Dual ectopic thyroid: case series and review of the literature. Clin Nucl Med (2007) 1.44
18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus? Nucl Med Commun (2011) 1.44
Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med (2010) 1.43
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett (2003) 1.43
MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal (2007) 1.43
Persistent renin-angiotensin system activation after anti-reflux surgery and its management. J Pediatr Urol (2011) 1.43
Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I. Radiat Prot Dosimetry (2005) 1.43
Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab (2004) 1.41
Long term outcome of management of antenatally diagnosed pelvi-ureteric junction obstruction. Indian J Pediatr (2011) 1.41
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem (2008) 1.41
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res (2005) 1.39
Direct radionuclide cystography by supra-pubic puncture: comparison with conventional voiding cystourethrography. Nucl Med Commun (2004) 1.39
Role of travel as a risk factor for hepatitis E virus infection in a disease-endemic area. Indian J Gastroenterol (2002) 1.39
Repression of Six3 by a corepressor regulates rhodopsin expression. Proc Natl Acad Sci U S A (2007) 1.38
Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res (2006) 1.38
National leadership: driving forward the updated Global Strategy for Women's, Children's and Adolescents' Health. BMJ (2015) 1.38
Steering estrogen signals from the plasma membrane to the nucleus: two sides of the coin. J Cell Physiol (2006) 1.36
LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer (2006) 1.34
Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem (2003) 1.34
Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res (2007) 1.34
Nuclear localization and chromatin targets of p21-activated kinase 1. J Biol Chem (2005) 1.34
p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep (2004) 1.34
Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem (2004) 1.33
Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Res (2007) 1.31
Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem (2006) 1.31
Synthesis and in vitro anti-mycobacterial activity of 5-substituted pyrimidine nucleosides. Bioorg Med Chem (2005) 1.30
p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep (2002) 1.30
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther (2010) 1.30
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res (2004) 1.30
Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature (2010) 1.29